These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28668717)

  • 21. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients.
    Mitchell AJ; Vancampfort D; De Herdt A; Yu W; De Hert M
    Schizophr Bull; 2013 Mar; 39(2):295-305. PubMed ID: 22927670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study.
    Chue P; Mandel FS; Therrien F
    Curr Med Res Opin; 2014 Jun; 30(6):997-1005. PubMed ID: 24568177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic syndrome in Italian patients with bipolar disorder: a 2-year follow-up study.
    Salvi V; D'Ambrosio V; Bogetto F; Maina G
    J Affect Disord; 2012 Feb; 136(3):599-603. PubMed ID: 22119084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort.
    Mallet J; Le Strat Y; Schürhoff F; Mazer N; Portalier C; Andrianarisoa M; Aouizerate B; Berna F; Brunel L; Capdevielle D; Chereau I; D'Amato T; Denizot H; Dubreucq J; Faget C; Gabayet F; Lançon C; Llorca PM; Misdrahi D; Rey R; Roux P; Schandrin A; Urbach M; Vidailhet P; Fond G; Dubertret C;
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):332-339. PubMed ID: 28663115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mediating role of depression in pathways linking positive and negative symptoms in schizophrenia. A longitudinal analysis using latent variable structural equation modelling.
    Carrà G; Crocamo C; Bartoli F; Angermeyer M; Brugha T; Toumi M; Bebbington P
    Psychol Med; 2020 Mar; 50(4):566-574. PubMed ID: 30846005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.
    Pallava A; Chadda RK; Sood M; Lakshmy R
    Nord J Psychiatry; 2012 Jun; 66(3):215-21. PubMed ID: 22017264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohort.
    Godin O; Pignon B; Szoke A; Boyer L; Aouizerate B; Schorr B; André M; Capdevielle D; Chereau I; Coulon N; Dassing R; Dubertret C; Etain B; Leignier S; Llorca PM; Mallet J; Misdrahi D; Passerieux C; Rey R; Urbach M; Schürhoff F; Leboyer M; Fond G
    Prog Neuropsychopharmacol Biol Psychiatry; 2023 Jan; 120():110641. PubMed ID: 36122839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia.
    Eskelinen S; Sailas E; Joutsenniemi K; Holi M; Suvisaari J
    Nord J Psychiatry; 2015 Jul; 69(5):339-45. PubMed ID: 25981178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort.
    Fond G; Resseguier N; Schürhoff F; Godin O; Andrianarisoa M; Brunel L; Bulzacka E; Aouizerate B; Berna F; Capdevielle D; Chereau I; D'Amato T; Dubertret C; Dubreucq J; Faget C; Gabayet F; Lançon C; Llorca PM; Mallet J; Misdrahi D; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Boyer L; Leboyer M;
    Eur Arch Psychiatry Clin Neurosci; 2018 Sep; 268(6):541-553. PubMed ID: 29127503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic syndrome in men with low testosterone levels: relationship with cardiovascular risk factors and comorbidities and with erectile dysfunction.
    García-Cruz E; Leibar-Tamayo A; Romero J; Piqueras M; Luque P; Cardeñosa O; Alcaraz A
    J Sex Med; 2013 Oct; 10(10):2529-38. PubMed ID: 23898860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic syndrome and cardiovascular risk among institutionalized patients with schizophrenia receiving long term tertiary care.
    Seow LS; Chong SA; Wang P; Shafie S; Ong HL; Subramaniam M
    Compr Psychiatry; 2017 Apr; 74():196-203. PubMed ID: 28214752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of metabolic syndrome and its clinical correlates among patients with bipolar disorder.
    Kumar A; Narayanaswamy JC; Venkatasubramanian G; Raguram R; Grover S; Aswath M
    Asian J Psychiatr; 2017 Apr; 26():109-114. PubMed ID: 28483070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A follow-up study of metabolic syndrome in schizophrenia.
    Yoca G; Anıl Yağcıoğlu AE; Eni N; Karahan S; Türkoğlu İ; Akal Yıldız E; Mercanlıgil SM; Yazıcı MK
    Eur Arch Psychiatry Clin Neurosci; 2020 Aug; 270(5):611-618. PubMed ID: 31030256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Change in Body Weight from Age 20 Years Is a Powerful Determinant of the Metabolic Syndrome.
    Lind L; Elmståhl S; Ärnlöv J
    Metab Syndr Relat Disord; 2017 Apr; 15(3):112-117. PubMed ID: 28339342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of metabolic syndrome in subjects with melancholic and non-melancholic depressive symptoms. A Finnish population-based study.
    Seppälä J; Vanhala M; Kautiainen H; Eriksson J; Kampman O; Mäntyselkä P; Oksa H; Ovaskainen Y; Viikki M; Koponen H
    J Affect Disord; 2012 Feb; 136(3):543-9. PubMed ID: 22119085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic Syndrome Development During Aging with Special Reference to Obesity Without the Metabolic Syndrome.
    Roos V; Elmståhl S; Ingelsson E; Sundström J; Ärnlöv J; Lind L
    Metab Syndr Relat Disord; 2017 Feb; 15(1):36-43. PubMed ID: 27754771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between depressive symptoms, use of antidepressant medication and the metabolic syndrome: the Maine-Syracuse Study.
    Crichton GE; Elias MF; Robbins MA
    BMC Public Health; 2016 Jun; 16():502. PubMed ID: 27287001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey.
    Yazici MK; Anil Yağcioğlu AE; Ertuğrul A; Eni N; Karahan S; Karaağaoğlu E; Tokgözoğlu SL
    Eur Arch Psychiatry Clin Neurosci; 2011 Feb; 261(1):69-78. PubMed ID: 20517698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.